Skip to main content
All lobbying filings

AMERICAN SOCIETY OF NEPHROLOGY

Lobbying for AMERICAN SOCIETY OF NEPHROLOGY

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $60,000.00 expenses · posted Jul 16, 2026

Official filing document

 Bills named in this filing 14
  • HR 7868
    Expanding Support for Living Donors Act of 2026
  • HR 4583
    Living Donor Protection Act of 2025
  • HR 4582
    To amend the Family and Medical Leave Act of 1993 and title 5, United States Code, to clarify that organ donation surge…
  • S 1552
    Living Donor Protection Act of 2025
  • HR 8367
    Answering the Call Act of 2026
  • HR 8875
    Improving Home Dialysis Act of 2026
  • HR 9509
    Kidney Disease Education Access Expansion Act of 2026
  • HR 8319
    KIDNEY Remote Monitoring Act
  • HR 8163
    Provider Reimbursement Stability Act of 2026
  • HR 7905
    Diabetes Foot Health Access and Modernization Act of 2026
  • HR 7961
    H–1Bs for Physicians and the Healthcare Workforce Act
  • HR 7581
    LOVE Act
  • HR 1518
    New Era of Preventing End-Stage Kidney Disease Act
  • HR 9169
    PKD Cures Act
 Lobbying activity 2
Health Issues

-Expanding Support for Living Donors Act (H.R. 7868) Legislation to expand how much living donors can be reimbursed and to increase the threshold for income-based qualification -Living Donor Protection Act (H.R. 4583) and related FMLA bill (H.R. 4582 and S. 1552). Clarifies and strengthens protections for Americans who donate an organ. -Concurrent Care for Comfort Act (HR 8367) and related policy concepts regarding helping patients on dialysis nearing end of life also access hospice care -Home Dialysis Improvement Act (HR 8875) and related policy concepts helping more patients consider electing home dialysis -Kidney Disease Education Expansion Act of 2026 (H.R. 9509) and related policy concepts to increase earlier upstream intervention to slow the progression of kidney disease, including screening and diagnosis -$77M in appropriations for HRSA Organ Transplant work in FY27 (funding to modernize the US transplant system and support living donors through reimbursement for living kidney donation-related costs) -$25M in appropriations for HHS in FY27 to support KidneyX (public-private partnership to catalyze innovation in kidney disease prevention, diagnosis, and treatment through a series of prize competitions) -Called for continued focus on modernizing the U.S. transplant system, including implementing the 2023 Securing the U.S. OPTN Act -Called for the creation of an Officer of Kidney Health and Transplantation within the immediate office of the secretary of HHS (to coordinate kidney health care, research, and data-related efforts across the numerous HHS agencies with a role in kidney health) -Urged HHS to ensure kidney health data remains accessible and complete, including advancing data-sharing, data standards, and interoperability -Encouraged CMMI to develop a subsequent kidney care focused model, building on the successes and lessons of the CKCC model -Asked questions about the adequacy of kidney patient access to specialized kidney and transplant care in MA plans -Endorsed the following bills: -Keeping Individuals with Dialysis Needs Equipped through Year-round (KIDNEY) Remote Monitoring Act (HR 8319) Provider Reimbursement Stability Act (HR 8163) -The Diabetes Foot Health Access and Modernization Act of 2026 (HR 7905/S 4070) -H-1Bs for Physicians and Healthcare Workforce Act (HR 7961) Living Organ Volunteer Engagement (LOVE) Act (HR 7581) -New Era of Preventing ESRD Act (HR 1518) -PKD Cures Act (HR 9169)

Science/Technology

-$51.303B in appropriations for NIH in FY27 (to support investments in basic, clinical, translational, and other health-related research activities) -$1 billion in appropriations for kidney research at NIDDK within the overall NIDDK FY27 appropriation, implementing the recommendations of the Transforming Kidney Health Research report -$25M in appropriations for HHS in FY27 to support KidneyX (public-private partnership to catalyze innovation in kidney disease prevention, diagnosis, and treatment through a series of prize competitions) -Called for significant revision or recision of the proposed Regulation for Federal Financial Assistance

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem